Related Experiment Videos

[Invasive fungal infections in patients with blood disorders]

F López1, I Jarque, G Martín

  • 1Servicios de Hematología y Microbiología, Hospital Universitario La Fe, Valencia.

Medicina Clinica
|June 3, 1998
PubMed
Abstract

Insights

Invasive fungal infections (IFI) in patients with hematologic disorders have a poor prognosis despite advances in treatment. Early antifungal therapy and managing neutropenia are key to improving outcomes for these severe infections.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Mycology

Context:

  • Invasive fungal infections (IFI) are significant complications in patients with hematological disorders.
  • This study analyzes 155 IFIs in 144 patients over 17 years at a single institution.

Purpose:

  • To characterize IFIs in hematologic malignancy patients.
  • To identify factors influencing IFI outcomes and therapeutic response.

Summary:

  • Acute leukemia was the most common diagnosis (82%).
  • Key risk factors included profound granulocytopenia, broad-spectrum antibiotics, central venous catheters, and chemotherapy-induced barrier damage.
  • Candida (44%) and Aspergillus (26%) were most common; previously overlooked fungi are emerging pathogens.
  • Favorable outcomes occurred in 50% of cases.
  • Prognostic factors included chemotherapy phase, underlying disease response, neutropenia recovery, and early empirical antifungal therapy.

Impact:

  • IFI prognosis in hematologic malignancies remains poor despite new treatments.
  • Hematopoietic growth factors may improve IFI management by reducing neutropenia duration and severity.

Related Concept Videos